

# Evan J Lipson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8605985/publications.pdf>

Version: 2024-02-01

80  
papers

15,371  
citations

100601

38  
h-index

134545

62  
g-index

82  
all docs

82  
docs citations

82  
times ranked

24133  
citing authors

#	ARTICLE	IF	CITATIONS
1	Acute axillary lymphadenopathy detected shortly after COVID-19 vaccination found to be due to newly diagnosed metastatic melanoma. <i>Radiology Case Reports</i> , 2022, 17, 878-880.	0.2	5
2	Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. <i>New England Journal of Medicine</i> , 2022, 386, 24-34.	13.9	766
3	Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma. <i>Cancer Immunology Research</i> , 2022, 10, 303-313.	1.6	1
4	Systemic Immune Dysfunction in Cancer Patients Driven by IL6 Induction of LAG3 in Peripheral CD8+ T Cells. <i>Cancer Immunology Research</i> , 2022, 10, 885-899.	1.6	7
5	Melanoma metastatic to the hyoid bone. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, 522-525.	0.2	2
6	A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2021, 27, 2571-2583.	3.2	22
7	Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. , 2021, 9, e002478.		59
8	Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).. <i>Journal of Clinical Oncology</i> , 2021, 39, 9503-9503.	0.8	116
9	Anti-PD-1 elicits regression of undifferentiated pleomorphic sarcomas with UV-mutation signatures. , 2021, 9, e002345.		7
10	Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade. <i>Science</i> , 2021, 372, .	6.0	114
11	Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers. , 2021, 9, e002473.		33
12	Spatial UMAP and Image Cytometry for Topographic Immuno-oncology Biomarker Discovery. <i>Cancer Immunology Research</i> , 2021, 9, 1262-1269.	1.6	8
13	The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas. <i>Clinical Cancer Research</i> , 2021, 27, 1516-1525.	3.2	6
14	Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade. <i>Clinical Cancer Research</i> , 2020, 26, 545-551.	3.2	100
15	Neuropilin-1 is a T cell memory checkpoint limiting long-term antitumor immunity. <i>Nature Immunology</i> , 2020, 21, 1010-1021.	7.0	85
16	Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding. <i>Science Immunology</i> , 2020, 5, .	5.6	36
17	Chronic immune checkpoint inhibitor pneumonitis. , 2020, 8, e000840.		55
18	Kidney retransplantation after antiâ€‘programmed cell death-1 (PD-1)â€‘related allograft rejection. <i>American Journal of Transplantation</i> , 2020, 20, 2264-2268.	2.6	20

#	ARTICLE	IF	CITATIONS
19	Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 332-338.	0.5	140
20	Shorter survival and later stage at diagnosis among unmarried patients with cutaneous melanoma: A US national and tertiary care center study. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1012-1020.	0.6	13
21	Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma. , 2020, 8, e001675.		9
22	681â€¦Single pipeline re-analysis revises microbiome associations with anti-tumor response to checkpoint inhibitors. , 2020, , .		0
23	Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma. <i>Human Pathology</i> , 2019, 91, 69-76.	1.1	14
24	Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series. , 2019, 7, 170.		36
25	Challenge of Rechallenge: When to Resume Immunotherapy Following an Immune-Related Adverse Event. <i>Journal of Clinical Oncology</i> , 2019, 37, 2714-2718.	0.8	23
26	Cardiovascular toxicities associated with immune checkpoint inhibitors. <i>Cardiovascular Research</i> , 2019, 115, 854-868.	1.8	311
27	Poliosis Circumscripta: A Mark of Melanoma. <i>American Journal of Medicine</i> , 2019, 132, 1417-1418.	0.6	3
28	Reply. <i>Hepatology</i> , 2019, 69, 2718-2719.	3.6	0
29	Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 693-702.	0.8	274
30	Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy. <i>Oncologist</i> , 2019, 24, 1259-1269.	1.9	127
31	The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis. <i>Journal of Clinical Investigation</i> , 2019, 129, 4305-4315.	3.9	100
32	A Multidisciplinary Toxicity Team for Cancer Immunotherapyâ€“Related Adverse Events. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 712-720.	2.3	71
33	Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 916-925.	0.4	257
34	State-of-the-Art Diagnosis and Treatment of Melanoma. <i>Journal of Computer Assisted Tomography</i> , 2018, 42, 331-339.	0.5	0
35	Immunotherapy for Merkel cell carcinoma: a turning point in patient care. , 2018, 6, 23.		34
36	Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 553-557.	1.6	119

#	ARTICLE	IF	CITATIONS
37	2568 Pembrolizumab for patients with leptomeningeal disease from advanced solid tumors. Journal of Clinical and Translational Science, 2018, 2, 44-45.	0.3	0
38	Further Lessons in Pneumocystis Pneumonia Prophylaxisâ€”Reply. JAMA Internal Medicine, 2018, 178, 1566.	2.6	0
39	Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab. , 2018, 6, 99.		129
40	Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series. , 2018, 6, 104.		55
41	Nodular Regenerative Hyperplasia Associated With Immune Checkpoint Blockade. Hepatology, 2018, 68, 2431-2433.	3.6	20
42	From validity to clinical utility: the influence of circulating tumor <scp>DNA</scp> on melanoma patient management in a realâ€”world setting. Molecular Oncology, 2018, 12, 1661-1672.	2.1	32
43	Corticosteroid Use and Pneumocystis Pneumonia Prophylaxis. JAMA Internal Medicine, 2018, 178, 1106.	2.6	7
44	<i>BRAF</i>â€”V600 mutational status affects recurrence patterns of melanoma brain metastasis. International Journal of Cancer, 2017, 140, 2716-2727.	2.3	24
45	Transcriptional Mechanisms of Resistance to Antiâ€”PD-1 Therapy. Clinical Cancer Research, 2017, 23, 3168-3180.	3.2	67
46	PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison. Clinical Cancer Research, 2017, 23, 4938-4944.	3.2	120
47	Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade. , 2017, 5, 23.		118
48	Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade. Oncologist, 2017, 22, 627-630.	1.9	74
49	Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma. JAMA Oncology, 2017, 3, 974.	3.4	65
50	Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point<sup>18</sup>F-FDG PET/CT Imaging in Patients with Advanced Melanoma. Journal of Nuclear Medicine, 2017, 58, 1421-1428.	2.8	209
51	Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Annals of the Rheumatic Diseases, 2017, 76, 43-50.	0.5	317
52	Melanoma subtypes demonstrate distinct PD-L1 expression profiles. Laboratory Investigation, 2017, 97, 1063-1071.	1.7	156
53	Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade. American Journal of Surgical Pathology, 2017, 41, 1381-1389.	2.1	54
54	Initial efficacy of anti-lymphocyte activation gene-3 (antiâ€”LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with antiâ€”PD-1/PD-L1 therapy.. Journal of Clinical Oncology, 2017, 35, 9520-9520.	0.8	188

#	ARTICLE	IF	CITATIONS
55	Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis. <i>World Journal of Gastroenterology</i> , 2017, 23, 2023.	1.4	68
56	PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2016, 374, 2542-2552.	13.9	1,048
57	Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. <i>Kidney International</i> , 2016, 90, 638-647.	2.6	524
58	Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer. <i>JAMA Neurology</i> , 2016, 73, 928.	4.5	238
59	Tumor Regression and Allograft Rejection after Administration of Anti-PD-1. <i>New England Journal of Medicine</i> , 2016, 374, 896-898.	13.9	244
60	Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation. , 2015, 3, 22.		95
61	Nivolumab: targeting PD-1 to bolster antitumor immunity. <i>Future Oncology</i> , 2015, 11, 1307-1326.	1.1	158
62	Antagonists of PD-1 and PD-L1 in Cancer Treatment. <i>Seminars in Oncology</i> , 2015, 42, 587-600.	0.8	259
63	Successful Administration of Ipilimumab to Two Kidney Transplantation Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2014, 32, e69-e71.	0.8	137
64	Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. <i>Science Translational Medicine</i> , 2014, 6, 224ra24.	5.8	3,665
65	Regulatory T cells—an important target for cancer immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 307-307.	12.5	5
66	Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 24-37.	12.5	380
67	Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab. <i>Journal of Clinical Oncology</i> , 2014, 32, 1020-1030.	0.8	2,015
68	A Case Report of Primary Recurrent Malignant Melanoma of the Urinary Bladder. <i>Urology Case Reports</i> , 2013, 1, 2-4.	0.1	13
69	Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody. <i>Clinical Cancer Research</i> , 2013, 19, 462-468.	3.2	485
70	A Patient with HIV Treated with Ipilimumab and Stereotactic Radiosurgery for Melanoma Metastases to the Brain. <i>Case Reports in Oncological Medicine</i> , 2013, 2013, 1-4.	0.2	12
71	PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival. <i>Cancer Immunology Research</i> , 2013, 1, 54-63.	1.6	333
72	Re-orienting the immune system. <i>Oncolmmunology</i> , 2013, 2, e23661.	2.1	29

#	ARTICLE	IF	CITATIONS
73	Evolutionary dynamics of cancer in response to targeted combination therapy. <i>ELife</i> , 2013, 2, e00747.	2.8	516
74	Surgical Resection of Malignant Melanoma Metastatic to the Pancreas: Case Series and Review of Literature. <i>Journal of Gastrointestinal Cancer</i> , 2012, 43, 431-436.	0.6	21
75	Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2011, 17, 6958-6962.	3.2	438
76	Art in Oncology: How Patients Add Life to Their Days. <i>Journal of Clinical Oncology</i> , 2011, 29, 1392-1393.	0.8	6
77	Lenalidomide-Induced Acute Interstitial Nephritis. <i>Oncologist</i> , 2010, 15, 961-964.	1.9	23
78	Estimating platelet production in patients with HIV-related thrombocytopenia using the immature platelet fraction. <i>American Journal of Hematology</i> , 2009, 84, 852-854.	2.0	3
79	The Immature Platelet Fraction in HIV Patients with Thrombocytopenia.. <i>Blood</i> , 2007, 110, 2095-2095.	0.6	1
80	Patient and graft outcomes following liver transplantation for sarcoidosis. <i>Clinical Transplantation</i> , 2005, 19, 487-491.	0.8	43